A comparison of drugs and procedures of care in the Italian hospice and hospital settings: the final three days of life for cancer patients

BMC Health Services Research

Bregje Onwuteaka-Philipsen²  H Roeline Pasman²  Massimo Costantini¹  Emily West² 

[1] Palliative Care Unit, IRCCS Arcispedale S. Maria Nuova, Reggio Emilia, Italy;Department of Public and Occupational Health, EMGO + Institute for Health and Care Research – Expertise Centre for Palliative Care, VU University Medical Centre, Van der Boechorststraat 7, Amsterdam, 1081 BT, The Netherlands

关键词: Palliative;    Therapies;    Drugs;    Cancer;    End-of-life;   

Others  :  1125864
DOI  :  10.1186/s12913-014-0496-2

 received in 2014-06-12, accepted in 2014-10-06,  发布年份 2014

【 摘 要 】

Background

A palliative approach at the end of life typically involves forgoing certain drugs and procedures and starting others - weighing burden against potential benefit. An assessment of the palliative approach may be undertaken by investigating which drugs and procedures are used in the dying phase, and at what frequencies.

Methods

Drugs were classified as potentially (in)appropriate based on expert classification. Procedures were classed as therapeutic or diagnostic. 271 consecutive cancer deaths from across 16 hospital general wards and 5 hospices in Italy gathered data on drugs and procedures in the final three days of life through a standardised form. Differences between the two groups were tested using chi-square testing, and logistic regressions were performed to control for patient characteristics.

Results

75.0% of patients in hospital received 3 or more potentially inappropriate drugs in their last three days of life, against 42.6% in hospice. Diagnostic procedures were carried out more frequently in hospital. Multivariate logistic regression showed that when data was controlled for patient characteristics, setting had a unique contribution to the differences found in use of drugs and procedures.

Conclusion

The data indicates a need for improvement in the hospital setting concerning recognising the need for palliative care, and ensuring a timely introduction of this approach.

【 授权许可】

   
2014 West et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1][http:/ / www.nice.org.uk/ guidance/ csgsp/ evidence/ supportive-andpalliative-care-the-m anual-2] webcite Improving Supportive and Palliative Care for Adults with Cancer. Available at: . Accessed April 14, 2014.
• [2]Higginson IJ, Costantini M: Dying with cancer, living well with advanced cancer. Eur J Cancer 2008, 44(10):1414-1424. doi:10.1016/j.ejca.2008.02.024
• [3]Teno JM, Clarridge BR, Casey V, Welch LC, Wetle T, Shield R, Mor V: Family perspectives on end-of-life care at the last place of care. JAMA 2004, 291(1):88-93. doi:10.1001/jama.291.1.88
• [4]Houttekier D, Cohen J, Van den Block L, Bossuyt N, Deliens L: Involvement of palliative care services strongly predicts place of death in Belgium. J Palliat Med 2010, 13(12):1461-1468. doi:10.1089/jpm.2010.0279
• [5]Gomes B, Higginson IJ: Where people die (1974–2030): past trends, future projections and implications for care. Palliat Med 2008, 22(1):33-41. doi:10.1177/0269216307084606
• [6][http:/ / books.google.nl/ books/ about/ The_Management_of_Terminal_Malignan t_Dis.html?id=9fFHHAAACAAJ&redir_es c=y] webcite The Management of Terminal Malignant Disease. 1985. Available at: . Accessed April 14, 2014.
• [7]Coackley A, Ellershaw J: The terminal phase. Medicine (Baltimore) 2008, 36(2):105-108. doi:10.1016/j.mpmed.2007.11.013
• [8]Chapman L, Ellershaw J: Care in the last hours and days of life. Medicine (Baltimore) 2011, 39(11):674-677. doi:10.1016/j.mpmed.2011.08.001
• [9]Raijmakers NJH, van Zuylen L, Furst CJ, Beccaro M, Maiorana L, Pilastri P, Rossi C, Flego G, van der Heide A, Costantini M: Variation in medication use in cancer patients at the end of life: a cross-sectional analysis. Support Care Cancer 2013, 21(4):1003-1011. doi:10.1007/s00520-012-1619-0
• [10]Olsen ML, Swetz KM, Mueller PS: Ethical decision making with end-of-life care: palliative sedation and withholding or withdrawing life-sustaining treatments. Mayo Clin Proc 2010, 85(10):949-954. doi:10.4065/mcp.2010.0201
• [11]Veerbeek L, van Zuylen L, Gambles M, Swart SJ, van der Heide A, van der Rijt CC, Ellershaw JE: Audit of the Liverpool care pathway for the dying patient in a dutch cancer hospital. J Palliat Care 2006, 22(4):305-308. Available at: http://www.ncbi.nlm.nih.gov/pubmed/17263060 . Accessed April 14, 2014
• [12]Di Leo S, Bono L, Romoli V, West E, Ambrosio R, Gallucci M, Pilastri P, Ciura PL, Morino P, Piazza M, Valenti D, Franceschini C, Costantini M: Implementation of the Liverpool care pathway (LCP) for the dying patient in the inpatient hospice setting: development and preliminary assessment of the Italian LCP program. Am J Hosp Palliat Care 2014, 31(1):61-68. doi:10.1177/1049909113482355
• [13]Costantini M, Ottonelli S, Canavacci L, Pellegrini F, Beccaro M: The effectiveness of the Liverpool care pathway in improving end of life care for dying cancer patients in hospital. A cluster randomised trial. BMC Health Serv Res 2011, 11(1):13. doi:10.1186/1472-6963-11-13 BioMed Central Full Text
• [14]Ballard DJ: Indicators to improve clinical quality across an integrated health care system. Int J Qual Heal Care 2003, 15(90001):13i-23i. doi:10.1093/intqhc/mzg080
• [15]Hui D, Dos Santos R, Chisholm G, Bansal S, Silva TB, Kilgore K, Crovador CS, Yu X, Swartz MD, Perez-Cruz PE, Leite Rde A, Nascimento MS, Reddy S, Seriaco F, Yennu S, Paiva CE, Dev R, Hall S, Fajardo J, Bruera E: Clinical signs of impending death in cancer patients. Oncologist 2014, 19(6):681-687. doi:10.1634/theoncologist.2013-0457. Epub 2014 Apr 23
• [16]Gomes B, Calanzani N, Curiale V, McCrone P, Higginson IJ: Effectiveness and cost-effectiveness of home palliative care services for adults with advanced illness and their caregivers. Cochrane Database Syst Rev 2013, 6:CD007760. doi:10.1002/14651858.CD007760.pub2
• [17]Higginson IJ, Evans CJ: What is the evidence that palliative care teams improve outcomes for cancer patients and their families? Cancer J 2010, 16(5):423-435.
• [18]Earle CC, Neville BA, Landrum MB, Ayanian JZ, Block SD, Weeks JC: Trends in the aggressiveness of cancer care near the end of life. J Clin Oncol 2004, 22(2):315-321. doi:10.1200/JCO.2004.08.136
• [19]Bausewein C, Booth S, Gysels M, Kühnbach R, Haberland B, Higginson IJ: Understanding breathlessness: cross-sectional comparison of symptom burden and palliative care needs in chronic obstructive pulmonary disease and cancer. J Palliat Med 2010, 13(9):1109-1118. doi:10.1089/jpm.2010.0068
• [20]Goldstein NE, Concato J, Fried TR, Kasl SV, Johnson-Hurzeler R, Bradley EH: Factors associated with caregiver burden among caregivers of terminally ill patients with cancer. J Palliat Care 2004, 20(1):38-43. Available at: http://europepmc.org/abstract/MED/15132075/reload=0 . Accessed April 14, 2014
• [21]Fineberg IC, Wenger NS, Brown-Saltzman K: Unrestricted opiate administration for pain and suffering at the end of life: knowledge and attitudes as barriers to care. J Palliat Med 2006, 9(4):873-883. doi:10.1089/jpm.2006.9.873
• [22][http:/ / scholar.google.co.uk/ scholar?lookup=0&q=Developing+an+in tegrated+care+pathway+for+the+dying +patient&hl=en&as_sdt=0,5] webcite Ellershaw J, Foster A: Developing an integrated care pathway for the dying patient.Eur 1997. Available at: . Accessed April 14, 2014.